Bausch Health Companies (TSE:BHC) Issues Quarterly Earnings Results

Bausch Health Companies (TSE:BHC) issued its quarterly earnings data on Wednesday. The company reported C$1.79 EPS for the quarter, FiscalAI reports. The business had revenue of C$2.85 billion for the quarter. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%.

Bausch Health Companies Price Performance

Shares of TSE BHC opened at C$6.56 on Thursday. The business has a 50-day moving average of C$6.96 and a 200-day moving average of C$7.57. Bausch Health Companies has a fifty-two week low of C$6.10 and a fifty-two week high of C$11.97. The company has a debt-to-equity ratio of -1,009.96, a current ratio of 1.32 and a quick ratio of 0.58. The stock has a market capitalization of C$2.45 billion, a price-to-earnings ratio of -2.02, a PEG ratio of 0.21 and a beta of 0.97.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group raised Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 22nd. Three research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of “Hold”.

Key Headlines Impacting Bausch Health Companies

Here are the key news stories impacting Bausch Health Companies this week:

• Positive Sentiment: Q2 results beat expectations: Bausch reported C$1.79 in quarterly EPS and C$2.85 billion in revenue. Coverage characterized both figures as above analyst estimates, supporting the stock’s immediate gains. Bausch Health Rises After Q2 Earnings, Revenue Beat Estimates
• Positive Sentiment: Potential reimbursement support: ELIDEL cream became eligible for reimbursement under Alberta’s public drug plan for qualifying patients with mild-to-moderate atopic dermatitis, potentially improving access and supporting product demand. ELIDEL Reimbursed Under Alberta’s Public Drug Plan
• Neutral Sentiment: Full-year outlook context: The broader analyst consensus cited for Bausch Health remains approximately $5.55 in current-year EPS, providing a benchmark for investors assessing whether the quarterly beat can be sustained. Bausch: Q2 Earnings Snapshot
• Negative Sentiment: Future earnings estimates were cut: Zacks Research lowered its EPS forecasts for several periods, including FY2027 to $5.06 from $5.10 and FY2028 to $4.26 from $4.34. Quarterly estimates were also reduced modestly, signaling softer expectations for longer-term profitability. Zacks Research Estimate for BHC Earnings
• Negative Sentiment: Financial risks remain: Despite the quarterly beat, Bausch has reported a negative net margin, while its shares remain below their 50-day and 200-day moving averages. Those factors could limit enthusiasm if investors focus on profitability and leverage concerns.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.